Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.4B 10.9B 10.13B 9.32B 17.47B 1,200B 17.78B 121B 47.24B 586B 46.54B 45.53B 2,031B P/E 2026 *
-73.4x
P/E 2027 * 63x
Enterprise Value 11.88B 10.45B 9.71B 8.93B 16.74B 1,151B 17.04B 116B 45.28B 561B 44.6B 43.64B 1,947B EV / Sales 2026 *
7.93x
EV / Sales 2027 * 5.19x
Free-Float
94.11%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 12.4B
+1.23%-3.08%+53.96%+87.98% 55.27B
+5.09%+6.18%+63.69%+62.06% 54.15B
+0.72%-0.05%+3.84%+424.98% 23.11B
+0.25%+0.55%-19.67%-13.99% 23.22B
+1.03%-0.76%+40.14%-3.59% 20.33B
-0.37%+0.42%+37.47%-31.61% 17.91B
+0.87%-2.80%+37.96%+600.00% 15.76B
-2.54%-12.88%+168.62%+289.45% 15B
+1.22%-0.05%+22.58%+179.79% 13.82B
Average +0.75%-0.37%+45.40%+177.23% 26.51B
Weighted average by Cap. +1.49%+1.19%+46.06%+139.85%

Financials

2026 *2027 *
Net sales 1.5B 1.32B 1.22B 1.13B 2.11B 145B 2.15B 14.64B 5.71B 70.78B 5.63B 5.5B 246B 2.18B 1.92B 1.78B 1.64B 3.07B 211B 3.13B 21.3B 8.31B 103B 8.18B 8.01B 357B
Net income -210M -184M -171M -158M -295M -20.3B -301M -2.05B -799M -9.9B -787M -770M -34.35B 264M 232M 216M 198M 372M 25.55B 379M 2.58B 1.01B 12.46B 991M 969M 43.24B
Net Debt -515M -453M -421M -387M -726M -49.89B -739M -5.03B -1.96B -24.33B -1.93B -1.89B -84.42B -1.08B -946M -879M -809M -1.52B -104B -1.54B -10.51B -4.1B -50.83B -4.04B -3.95B -176B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
537.65USD
Average target price
679.64USD
Spread / Average Target
+26.41%

Quarterly revenue - Rate of surprise